Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
APG-115 (Alrizomadlin) |
MDM2 Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
APG-115 (Alrizomadlin)
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
MDM2 Inhibitor |
||||
Tretinoin (All-Trans Retinoic Acid) |
Retinoid / Arsenical | Hematologic (APL) / Solid Tumour | ||
|
Molecule
Tretinoin (All-Trans Retinoic Acid)
Therapeutic Category
Differentiating Agent
Oncology Type
Hematologic (APL) / Solid Tumour
Drug Class / Mechanism
Retinoid / Arsenical |
||||
Arsenic Trioxide |
Retinoid / Arsenical | Hematologic (APL) / Solid Tumour | ||
|
Molecule
Arsenic Trioxide
Therapeutic Category
Differentiating Agent
Oncology Type
Hematologic (APL) / Solid Tumour
Drug Class / Mechanism
Retinoid / Arsenical |
||||
Bexarotene |
Retinoid / Arsenical | Hematologic (APL) / Solid Tumour | ||
|
Molecule
Bexarotene
Therapeutic Category
Differentiating Agent
Oncology Type
Hematologic (APL) / Solid Tumour
Drug Class / Mechanism
Retinoid / Arsenical |
||||
Alitretinoin |
Retinoid / Arsenical | Hematologic (APL) / Solid Tumour | ||
|
Molecule
Alitretinoin
Therapeutic Category
Differentiating Agent
Oncology Type
Hematologic (APL) / Solid Tumour
Drug Class / Mechanism
Retinoid / Arsenical |
||||
Isotretinoin (Onc Adjacent) |
Retinoid / Arsenical | Hematologic (APL) / Solid Tumour | ||
|
Molecule
Isotretinoin (Onc Adjacent)
Therapeutic Category
Differentiating Agent
Oncology Type
Hematologic (APL) / Solid Tumour
Drug Class / Mechanism
Retinoid / Arsenical |
||||
Fenretinide |
Retinoid / Arsenical | Hematologic (APL) / Solid Tumour | ||
|
Molecule
Fenretinide
Therapeutic Category
Differentiating Agent
Oncology Type
Hematologic (APL) / Solid Tumour
Drug Class / Mechanism
Retinoid / Arsenical |
||||
Radium-223 Dichloride |
Radiotherapeutic / Radiodiagnostic Agent | Both (Solid & Hematologic) | ||
|
Molecule
Radium-223 Dichloride
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
||||
Lutetium-177 Dotatate |
Radiotherapeutic / Radiodiagnostic Agent | Both (Solid & Hematologic) | ||
|
Molecule
Lutetium-177 Dotatate
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
||||
Lutetium-177 Vipivotide Tetraxetan |
Radiotherapeutic / Radiodiagnostic Agent | Both (Solid & Hematologic) | ||
|
Molecule
Lutetium-177 Vipivotide Tetraxetan
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
||||
Iodine-131 Tositumomab |
Radiotherapeutic / Radiodiagnostic Agent | Both (Solid & Hematologic) | ||
|
Molecule
Iodine-131 Tositumomab
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
||||
Ibritumomab Tiuxetan (Y-90) |
Radiotherapeutic / Radiodiagnostic Agent | Both (Solid & Hematologic) | ||
|
Molecule
Ibritumomab Tiuxetan (Y-90)
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
||||
APG-115 (Alrizomadlin)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
MDM2 Inhibitor |
|
Tretinoin (All-Trans Retinoic Acid)Differentiating Agent |
|
|
Therapeutic Category
Differentiating Agent
Oncology Type
Hematologic (APL) / Solid Tumour
Drug Class / Mechanism
Retinoid / Arsenical |
|
Arsenic TrioxideDifferentiating Agent |
|
|
Therapeutic Category
Differentiating Agent
Oncology Type
Hematologic (APL) / Solid Tumour
Drug Class / Mechanism
Retinoid / Arsenical |
|
BexaroteneDifferentiating Agent |
|
|
Therapeutic Category
Differentiating Agent
Oncology Type
Hematologic (APL) / Solid Tumour
Drug Class / Mechanism
Retinoid / Arsenical |
|
AlitretinoinDifferentiating Agent |
|
|
Therapeutic Category
Differentiating Agent
Oncology Type
Hematologic (APL) / Solid Tumour
Drug Class / Mechanism
Retinoid / Arsenical |
|
Isotretinoin (Onc Adjacent)Differentiating Agent |
|
|
Therapeutic Category
Differentiating Agent
Oncology Type
Hematologic (APL) / Solid Tumour
Drug Class / Mechanism
Retinoid / Arsenical |
|
FenretinideDifferentiating Agent |
|
|
Therapeutic Category
Differentiating Agent
Oncology Type
Hematologic (APL) / Solid Tumour
Drug Class / Mechanism
Retinoid / Arsenical |
|
Radium-223 DichlorideRadiopharmaceutical / Nuclear Medicine |
|
|
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
|
Lutetium-177 DotatateRadiopharmaceutical / Nuclear Medicine |
|
|
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
|
Lutetium-177 Vipivotide TetraxetanRadiopharmaceutical / Nuclear Medicine |
|
|
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
|
Iodine-131 TositumomabRadiopharmaceutical / Nuclear Medicine |
|
|
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
|
Ibritumomab Tiuxetan (Y-90)Radiopharmaceutical / Nuclear Medicine |
|
|
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
|